  The SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19.
Exploring compounds that could offer a breakthrough in treatment is the need of
the hour. Re-positioning cheap, freely available and safe drugs is a priority.
The paper proposes evidence for the potential use of diethylcarbamazine (DEC)
in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid
metabolism to prostaglandins, little known anti-viral effects on animal
retroviruses and demonstrated anti-inflammatory actions in animal models of
lung inflammation indicating the need to explore this hypothesis further. We
believe this is the first time DEC is being proposed to treat COVID-19.
